CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Prednisone tabletWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (5)

Name (Synonyms) Correlation
drug1186 Goal-Oriented Attentional Self-Regulation (GOALS) Wiki 1.00
drug3266 fMRI Wiki 1.00
drug461 Brain Health Education (BHE) Wiki 1.00
drug3472 standard of care Wiki 0.71
drug703 Colchicine Wiki 0.32

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D000070642 Brain Injuries, Traumatic NIH 0.38
D001930 Brain Injuries, NIH 0.33

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Phase 2/3, Randomized, Open Study to Compare the Efficacy and Safety of Colchicine and Glucocorticoids Compared With the Standard of Treatment for Moderate/Severe COVID-19 in a Fragile and Vulnerable Population, Admitted to a Geriatric Hospital Unit or in a Transicional Care Center

Study to compare the efficacy and safety of colchicine and glucocorticoids compared with the standard of treatment for moderate/severe COVID-19 in a fragile and vulnerable population, admitted to a geriatric hospital unit or in a transicional care center

NCT04492358 Covid19 Drug: Colchicine Drug: Prednisone tablet Drug: standard of care

Primary Outcomes

Description: Number of patients that a short cycle of steroids (with prednisone 60 mg/d, in a single dose, for 3 consecutive days) administered together with colchicine (at doses of 0.5 to 1.5 mg/d, adjusted for weight and renal function, for 3 days and maintenance of 0.5 mg/d for 14 days in total) reduces mortality from COVID-19 in this population by at least 20%, compared to the approved standard treatment at participating centers.

Measure: Number of patients that a short cycle of steroids administered together with colchicine reduces mortality from COVID-19

Time: 28 days

Secondary Outcomes

Description: Number and grade of adverse events at group of colchicine and glucocorticoids throughout the treatment and in the two weeks following treatment according to the incidence of: mild adverse event serious adverse events hypersensitivity (allergic) reactions of grade >=2

Measure: Number and grade of adverse events at group of colchicine and glucocorticoids throughout the treatment and in the two weeks following treatment

Time: 28 days

Description: Percentage of patients who stop medication due to adverse events.

Measure: Percentage of patients who stop medication due to adverse events.

Time: 28 days

Description: Severity of symptoms by COVID-19 in the two treatment arms (response to treatment to be assessed by overall survival at 28 days from the start of treatment).

Measure: Severity of symptoms by COVID-19 in the two treatment arms

Time: 28 days

No related HPO nodes (Using clinical trials)